BioTuesdays

Tag - Stifel

Affimed

Stifel starts Affimed at buy; PT $12

Stifel launched coverage of Affimed NV (NASDAQ:AFMD) with a “buy” rating and price target of $12. The stock closed at $5.85 on Sept. 29. Affimed is a clinical-stage biotechnology company focused on bispecific antibody...

Stifel starts Repare Therapeutics at buy; PT $48

Stifel launched coverage of Repare Therapeutics (NASDAQ:RPTX) with a “buy” rating and $48 price target. The stock finished at $28.48 on Sept. 22. Analyst Benjamin Burnett, Ph.D., writes that his rating is largely...

Kinnate-Biopharma

Stifel starts Kinnate Biopharma at buy; PT $32

Stifel launched coverage of Kinnate Biopharma (NASDAQ:KNTE) with a “buy” rating and $32 price target. The stock closed at $23.44 on Sept. 22. “Our positive thesis is based on the belief that the Phase 1 data for KIN...

Pennant Group logo

Stifel starts Pennant Group at buy; PT $37

Stifel launched coverage of Pennant Group (NASDAQ:PNTG) with a “buy” rating and price target of $37. The stock closed at $29.88 on Sept. 20. “We believe home health and hospice are the fastest-growing areas of...

Eliem-Therapeutics

Stifel starts Eliem Therapeutics at buy; PT $35

Stifel launched coverage of Eliem Therapeutics (NASDAQ:ELYM) with a “buy” rating and price target of $35. The stock closed at $27.56 on Sept. 3. Eliem is a clinical-stage biotechnology company focused on developing...

Surrozen

Stifel starts Surrozen at buy; PT $19

Stifel launched coverage of Surrozen (NASDAQ:SRZN) with a “buy” rating and $19 target price. The stock closed at $7.24 on Sept. 3. Surrozen discovers and develops biologic drug candidates to selectively modulate the Wnt...

Rani-Therapeutics

Analysts start Rani Therapeutics at buy; PT $24

Analysts for Stifel and BTIG launched coverage of Rani Therapeutics (NASDAQ:RANI) with “buy” ratings and price targets of $24, respectively. The stock closed at $17.76 on Aug. 24. “Rani appears to have cracked the...

Acumen

Stifel starts Acumen Pharma at buy; PT $27

Stifel launched coverage of Acumen Pharmaceuticals (NASDAQ:ABOS) with a “buy” rating and $27 price target. The stock closed at $17.08 on July 23. Acumen is a biotechnology company focused on the development of a next...

GH-Research

Stifel starts GH Research at buy; PT $26

Stifel launched coverage of GH Research PLC (NASDAQ:GHRS) with a “buy” rating and price target of $26. The stock closed at $17.25 on July 19. “We believe GH offers an attractive way to invest in the psychedelics space...